Beacon VP Investments
Biotech, event-driven, micro-cap, small-cap

Anacor's Drug Tavaborole Should Receive FDA Approval

On May 29, 2013, Anacor Pharmaceuticals (NASDAQ:ANAC) announced successful completion of pre-NDA (New Drug Application) communication with the United States Food and Drug Administration (FDA) related to tavaborole, Anacor's lead drug candidate for the treatment of onychomycosis. More recently, on July 26, 2013, Anacor indicated that it had submitted its NDA to the FDA. The FDA has sixty days to decide whether to accept this NDA for review. Based on analysis of scientific literature and clinical data on drug efficacy and safety, we believe the NDA for tavaborole will be accepted for review and will then be approved by mid-2014.

Background

Anacor is a biopharmaceutical company with eight drug candidates in its pipeline. Its lead product candidates include...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details